SHIM
SMMT icon

Stone House Investment Management’s Summit Therapeutics SMMT Stock Holding History

Stone House Investment Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58 Sell
4
-14
-78% -$248 ﹤0.01% 1314
2026
Q1 		$341 Buy
18
+12
+200% +$194 ﹤0.01% 874
2025
Q4 		$105 Buy
+6
New +$113 ﹤0.01% 830

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Stone House Investment Management's SMMT Position: Q2 2026 in Review

Stone House Investment Management reduced its Summit Therapeutics (SMMT) stake by 78% in Q2 2026, selling an estimated $248 and leaving 4 shares worth $58. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Stone House Investment Management first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. The position peaked at $341 in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Stone House Investment Management held 4 shares of Summit Therapeutics worth $58 as of Q2 2026.
  • Stone House Investment Management sold 14 Summit Therapeutics shares in Q2 2026, an estimated $248.
  • Summit Therapeutics made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1314 holding.
  • Stone House Investment Management first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Stone House Investment Management's Summit Therapeutics position peaked at $341 in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.